AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LYOPHILIZED FORM (VERSIONS) Russian patent published in 2021 - IPC C12N15/86 C12N7/00 A61K39/215 A61P31/14 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, immunology and virology. Described is a means for inducing specific immunity against SARS-CoV-2 severe acute respiratory syndrome virus in lyophilized form, containing as the only active component an expression vector based on the genome of the recombinant human adenovirus strain of the 26th serotype, in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an inserted expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. Also presented is a variant of an agent for inducing specific immunity against the SARS-CoV-2 severe acute respiratory syndrome virus in lyophilized form, containing as the only active component an expression vector based on the genome of the recombinant human adenovirus strain of serotype 5, in which the E1 and E3 regions are deleted , with an embedded expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. In addition, a variant of the agent for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in lyophilized form is described, containing as the only active component an expression vector based on the genome of the recombinant simian adenovirus strain of serotype 25, in which E1 and E3 region, with a built-in expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3. In this case, in the particular case of its implementation, the buffer solution of the agent for the reconstituted lyophilized form contains, wt. %: tris from 0.0180 to 0.0338; sodium chloride 0.1044 to 0.1957; sucrose 5.4688 to 10.2539; magnesium chloride hexahydrate from 0.0015 to 0.0028; EDTA from 0.0003 to 0.0005; polysorbate-80 from 0.0037 to 0.0070; water - the rest. In this case, the agent is intended for use intranasally or intramuscularly. Also, the agent can be administered jointly and simultaneously intranasally and intramuscularly.

EFFECT: development of reactions of humoral and cellular immune response against SARS-CoV-2 virus in the general population.

8 cl, 4 dwg, 6 tbl, 12 ex